Yeo C J, Cameron J L, Sohn T A, Lillemoe K D, Pitt H A, Talamini M A, Hruban R H, Ord S E, Sauter P K, Coleman J, Zahurak M L, Grochow L B, Abrams R A
Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-4606, USA.
Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60. doi: 10.1097/00000658-199709000-00004.
OBJECTIVE: The authors reviewed the pathology, complications, and outcomes in a consecutive group of 650 patients undergoing pancreaticoduodenectomy in the 1990s. SUMMARY BACKGROUND DATA: Pancreaticoduodenectomy has been used increasingly in recent years to resect a variety of malignant and benign diseases of the pancreas and periampullary region. METHODS: Between January 1990 and July 1996, inclusive, 650 patients underwent pancreaticoduodenal resection at The Johns Hopkins Hospital. Data were recorded prospectively on all patients. All pathology specimens were reviewed and categorized. Statistical analyses were performed using both univariate and multivariate models. RESULTS: The patients had a mean age of 63 +/- 12.8 years, with 54% male and 91% white. The number of resections per year rose from 60 in 1990 to 161 in 1995. Pathologic examination results showed pancreatic cancer (n = 282; 43%), ampullary cancer (n = 70; 11%), distal common bile duct cancer (n = 65; 10%), duodenal cancer (n = 26; 4%), chronic pancreatitis (n = 71; 11%), neuroendocrine tumor (n = 31; 5%), periampullary adenoma (n = 21; 3%), cystadenocarcinoma (n = 14; 2%), cystadenoma (n = 25; 4%), and other (n = 45; 7%). The surgical procedure involved pylorus preservation in 82%, partial pancreatectomy in 95%, and portal or superior mesenteric venous resection in 4%. Pancreatic-enteric reconstruction, when appropriate, was via pancreaticojejunostomy in 71% and pancreaticogastrostomy in 29%. The median intraoperative blood loss was 625 mL, median units of red cells transfused was zero, and the median operative time was 7 hours. During this period, 190 consecutive pancreaticoduodenectomies were performed without a mortality. Nine deaths occurred in-hospital or within 30 days of operation (1.4% operative mortality). The postoperative complication rate was 41%, with the most common complications being early delayed gastric emptying (19%), pancreatic fistula (14%), and wound infection (10%). Twenty-three patients required reoperation in the immediate postoperative period (3.5%), most commonly for bleeding, abscess, or dehiscence. The median postoperative length of stay was 13 days. A multivariate analysis of the 443 patients with periampullary adenocarcinoma indicated that the most powerful independent predictors favoring long-term survival included a pathologic diagnosis of duodenal adenocarcinoma, tumor diameter <3 cm, negative resection margins, absence of lymph node metastases, well-differentiated histology, and no reoperation. CONCLUSIONS: This single institution, high-volume experience indicates that pancreaticoduodenectomy can be performed safely for a variety of malignant and benign disorders of the pancreas and periampullary region. Overall survival is determined largely by the pathology within the resection specimen.
目的:作者回顾了20世纪90年代连续650例行胰十二指肠切除术患者的病理、并发症及治疗结果。 总结背景资料:近年来,胰十二指肠切除术越来越多地用于切除胰腺和壶腹周围区域的各种恶性和良性疾病。 方法:1990年1月至1996年7月(含)期间,650例患者在约翰霍普金斯医院接受了胰十二指肠切除术。前瞻性记录所有患者的数据。对所有病理标本进行复查并分类。采用单变量和多变量模型进行统计分析。 结果:患者的平均年龄为63±12.8岁,男性占54%,白人占91%。每年的手术例数从1990年的60例增加到1995年的161例。病理检查结果显示胰腺癌(n = 282;43%)、壶腹癌(n = 70;11%)、远端胆总管癌(n = 65;10%)、十二指肠癌(n = 26;4%)、慢性胰腺炎(n = 71;11%)、神经内分泌肿瘤(n = 31;5%)、壶腹周围腺瘤(n = 21;3%)、囊腺癌(n = 14;2%)、囊腺瘤(n = 25;4%)以及其他疾病(n = 45;7%)。手术方式包括保留幽门82%、部分胰腺切除95%以及门静脉或肠系膜上静脉切除4%。在合适的情况下,胰肠重建采用胰管空肠吻合术的占71%,胰管胃吻合术的占29%。术中中位失血量为625 mL,红细胞输注中位数为0单位,中位手术时间为7小时。在此期间,连续进行了190例胰十二指肠切除术且无死亡病例。9例患者在住院期间或术后30天内死亡(手术死亡率为1.4%)。术后并发症发生率为41%,最常见的并发症为早期胃排空延迟(19%)、胰瘘(14%)和伤口感染(10%)。23例患者在术后早期需要再次手术(3.5%),最常见的原因是出血、脓肿或伤口裂开。术后中位住院时间为13天。对443例壶腹周围腺癌患者进行多变量分析表明,有利于长期生存的最有力独立预测因素包括十二指肠腺癌的病理诊断、肿瘤直径<3 cm、切缘阴性、无淋巴结转移、组织学高分化以及未再次手术。 结论:这一单一机构的大量病例经验表明,胰十二指肠切除术可安全地用于治疗胰腺和壶腹周围区域的各种恶性和良性疾病。总体生存率很大程度上取决于切除标本的病理情况。
Ann Surg. 1998-6
Arch Surg. 2004-7
Ann Surg. 1999-5
Cochrane Database Syst Rev. 2025-6-10
Eur J Gastroenterol Hepatol. 2025-4-1
World J Methodol. 2024-9-20
Ann Surg. 1935-10
Rev Surg. 1963
Ann Surg. 1997-5
Int J Radiat Oncol Biol Phys. 1996-4-1
Am J Surg. 1996-1